Relying on Pharmacotherapy to Improve Motor Gains in Chronic Stroke Survivors
ConditionStroke
Trial statusNot yet recruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age21-80
SponsorSpaulding Rehabilitation Hospital
About this trial
The goal of this trial is to study if the concomitant administration of Telmisartan, Cilostazol IR (immediate release), and Metformin ER (extended release) can help stroke survivors make greater gains in movement and recovery during robot-assisted arm and hand rehabilitation.
Eligibility criteria
Qualifiers
Adults between 21 and 80 years of age.
History of ischemic stroke.
Stroke occurred at least six months prior to recruitment.
Moderate to severe UE impairment (FMA-UE score between 15 and 40)
Disqualifiers
Contraindications to the pharmacotherapy (e.g., heart failure, known medication reaction or interactions with ongoing medication regimen).
Taking dual antiplatelet therapy (e.g., Aspirin+Plavix) and/or other anticoagulation medications (e.g., Eliquis, coumadin) that cannot safely be modified or discontinued (as determined by the participant's primary care physician or by the medical monitor).
Clinically significant somnolence and/or depression that would hinder active participation in motor training sessions.
Taking any medication that the study physician determines to have a significant drug-drug interaction with Telmisartan, Cilostazol, and/or Metformin.
Trial design
Treatments tested in this trial
- Telmisartan, Metformin, Cilostazol
Treatment groups
50 Participants
are divided into 1 treatment groupSponsors and collaborators
Spaulding Rehabilitation Hospital
Lead sponsor
Neuro-Innovators, Inc.
Collaborator
Source ClinicalTrials.gov